

Guillaume Marquis-Gravel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8600806/publications.pdf>

Version: 2024-02-01

57
papers

1,086
citations

623734

14
h-index

434195

31
g-index

57
all docs

57
docs citations

57
times ranked

1673
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2018, 34, 214-233.	1.7	181
2	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 1981-1990.	27.0	145
3	Medical Treatment of Aortic Stenosis. Circulation, 2016, 134, 1766-1784.	1.6	113
4	Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1277-1287.	2.9	73
5	Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation, 2021, 143, 2229-2240.	1.6	64
6	Technology-Enabled Clinical Trials. Circulation, 2019, 140, 1426-1436.	1.6	59
7	Rationale and Design of the Aspirin Dosing – A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology, 2020, 5, 598.	6.1	59
8	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 2020, 76, 162-171.	2.8	50
9	Ultrasound guidance versus anatomical landmark approach for femoral artery access in coronary angiography: A randomized controlled trial and a meta-analysis. Journal of Interventional Cardiology, 2018, 31, 496-503.	1.2	35
10	Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation, 2019, 140, 1115-1124.	1.6	33
11	The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the <sc>BRO-CHF</sc> retrospective cohort study. ESC Heart Failure, 2019, 6, 27-36.	3.1	30
12	The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies. Canadian Journal of Cardiology, 2015, 31, 1421-1426.	1.7	23
13	Use of Direct Oral Anticoagulant and Outcomes in Patients With Atrial Fibrillation after Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. Journal of the American Heart Association, 2022, 11, e023561.	3.7	20
14	Stem Cell Therapy for the Treatment of Nonischemic Cardiomyopathy: A Systematic Review of the Literature and Meta-analysis of Randomized Controlled Trials. Canadian Journal of Cardiology, 2014, 30, 1378-1384.	1.7	19
15	Technical consideration in acute myocardial infarction with cardiogenic shock: A review of antithrombotic and PCI therapies. Catheterization and Cardiovascular Interventions, 2020, 95, 924-931.	1.7	15
16	Intensive lifestyle intervention including high-intensity interval training program improves insulin resistance and fasting plasma glucose in obese patients. Preventive Medicine Reports, 2015, 2, 314-318.	1.8	13
17	Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials. International Journal of Cardiology, 2018, 262, 110-116.	1.7	13
18	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€”From Population to Patient-Centered Approaches. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805525.	2.4	12
20	Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial. <i>Trials</i> , 2021, 22, 90.	1.6	9
21	Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011232.	3.9	9
22	Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, CIRCOUTCOMES121008190.	2.2	9
23	Prophylactic Mechanical Circulatory Support Use in Elective Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, e011534.	3.9	9
24	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	1.7	8
25	The Current State of Stem Cell Therapeutics: Canadian Approaches in the International Context. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1361-1369.	1.7	6
26	Collectively Operated Fellow-Initiated Research as a Novel Teaching Model to Bolster Interest and Increase Proficiency in Academic Research. <i>Canadian Journal of Cardiology</i> , 2017, 33, 685-687.	1.7	6
27	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022, 38, S79-S88.	1.7	6
28	Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. <i>Journal of Clinical Medicine</i> , 2019, 8, 2016.	2.4	5
29	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006582.	2.2	5
30	Novel Artificial Intelligence Applications in Cardiology: Current Landscape, Limitations, and the Road to Real-World Applications. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 513-525.	2.4	5
31	The Ongoing Saga of the Evolution of Percutaneous Coronary Intervention: From Balloon Angioplasty to Recent Innovations to Future Prospects. <i>Canadian Journal of Cardiology</i> , 2022, 38, S30-S41.	1.7	5
32	Everolimusâ€”eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, singleâ€”center initial experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 433-439.	1.2	3
33	Left ventricular mechanics in the acute phase of Takotsubo cardiomyopathy: distinctive ballooning patterns translate into different diastolic properties. <i>Heart and Vessels</i> , 2020, 35, 537-543.	1.2	3
34	Towards a better standard for defining high bleeding risk patients: can we now translate this into a better practice?. <i>European Heart Journal</i> , 2020, 41, 3750-3752.	2.2	3
35	Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. <i>CJC Open</i> , 2021, 3, 814-821.	1.5	3
36	Impact of rubidium imaging availability on management of patients with acute chest pain. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3281-3290.	2.1	3

#	ARTICLE	IF	CITATIONS
37	Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1443-1453.	3.4	3
38	Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 228-234.	0.8	2
39	“Ticagrelor or Prasugrel, Doctor?” The Basis for Decision in Clinical Practice. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1283-1285.	1.7	2
40	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) <i>TJ ETQq0 0 0 1.6 BT /Overclock 10 TF</i>	1.6	2
41	Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and) <i>Tj ETQq1 1 0,784314,rgBT /Over</i>	1.6	2
42	How Coronary Stents Became a Reality: A Firsthand Account by an Innovator in the Field. <i>Canadian Journal of Cardiology</i> , 2022, 38, S3-S4.	1.7	2
43	Thoracic Aortic Diseases: What the Practicing Cardiologist Needs to Know. <i>Canadian Journal of Cardiology</i> , 2022, 38, S99-S101.	1.7	2
44	Left Ventricular Dilatation Assessed on the Lateral Chest Radiograph: The Classic Hoffman and Rigler Sign Falls Short in a Modern-Day Population. <i>Canadian Journal of Cardiology</i> , 2016, 32, 378-383.	1.7	1
45	Bioresorbable vascular scaffold to treat in-stent restenosis: Single-center experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 558-563.	1.2	1
46	Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction. <i>Acta Cardiologica</i> , 2018, 73, 276-281.	0.9	1
47	Overcoming the Risk-Treatment Paradox for Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1462-1464.	2.8	1
48	Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation: Which COAPT-Ineligible Patients Might Benefit From the Procedure?. <i>Canadian Journal of Cardiology</i> , 2022, 38, 297-299.	1.7	1
49	The Ongoing Quest for Optimal Thrombus Prevention After ST-Elevation Myocardial Infarction in the Modern Era. <i>Canadian Journal of Cardiology</i> , 2018, 34, 93.e3.	1.7	0
50	Nuts and Bolts of Scientific Authorship: Doing It Right. <i>Canadian Journal of Cardiology</i> , 2018, 34, 347-348.	1.7	0
51	What Do Patients Expect from a Transcatheter Aortic Valve Replacement? The Importance of Considering Meaningful Nonmortality Outcomes. <i>Canadian Journal of Cardiology</i> , 2019, 35, 681-683.	1.7	0
52	The Prognostic Value of Intraventricular Conduction Disturbances: A Matter of Time?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1196-1198.	1.7	0
53	Rethinking Our Cardiovascular Risk Assessment in the Younger Female Migraine Population. <i>Headache</i> , 2020, 60, 994-997.	3.9	0
54	Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. <i>American Heart Journal</i> , 2020, 223, 84-86.	2.7	0

#	ARTICLE	IF	CITATIONS
55	Precision Medicine in TAVR: How to Select the Right Device for the Right Patient. Canadian Journal of Cardiology, 2021, 37, 4-6.	1.7	0
56	Percutaneous Management of Septic Left Anterior Descending Coronary Occlusion Following Minimally Invasive Surgery for Mitral Valve Infective Endocarditis. Canadian Journal of Cardiology, 2022, 38, 126-128.	1.7	0
57	Dual Antiplatelet Therapy after PCI: When Could We Go Shorter?. , 0, , .		0